Periodontal repair in dogs

Evaluation of a bioresorbable calcium phosphate cement (Ceredex™) as a carrier for rhBMP-2

Rachel G. Sorensen, Ulf M E Wikesjö, Atsuhiro Kinoshita, John M. Wozney

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Background: Recombinant human bone morphogenetic protein-2 (rhBMP-2) has been shown to induce clinically relevant bone formation for orthopedic, craniofacial, and oral indications. It appears critical, in particular for onlay indications, that the associated carrier technology exhibits structural integrity to offset compressive forces in support of rhBMP-2-induced bone formation. The objective of this study was to evaluate a calcium phosphate (CP) cement, Ceredex™, as a candidate carrier for rhBMP-2 in a defect model with limited osteogenic potential. Materials: Bilateral, critical size, 6-mm, supra-alveolar, periodontal defects were created in six, adult, male, Hound Labrador mongrels. Three animals received rhBMP-2/Ceredex™ (rhBMP-2 at 0.20 and 0.40 mg/ml) in contralateral defect sites (implant volume/defect ∼ 1 ml). One defect site in each of the three remaining animals received Ceredex™ without rhBMP-2 (control). The animals were euthanized at 1.2 weeks postsurgery for histologic and histometric analysis. Results: Mean induced bone height exceeded 80% of the defect height for supra-alveolar periodontal defects receiving rhBMP-2/Ceredex™ without major differences between rhBMP-2 concentrations compared with approximately 40% for the control. The newly formed bone, a mixture of lamellar and woven bone in fibrovascular tissue, circumscribed relatively large portions of the residual Ceredex™ biomaterial. Inflammatory lesions were associated with limited bone formation in some sites. From a periodontal perspective, sites receiving rhBMP-2/Ceredex™ exhibited increased cementum formation compared with control, but without a functionally oriented periodontal ligament, and increased ankylosis and root resorption. Control sites exhibited early wound failure and exposure, loss of the Ceredex™ biomaterial, and limited bone formation. Conclusions: The Ceredex™ CP cement appears a potentially promising carrier technology for rhBMP-2 onlay indications. However, a slow resorption rate may prevent its wider use. This study does not support use of the rhBMP-2/Ceredex™ combination for periodontal indications.

Original languageEnglish (US)
Pages (from-to)796-804
Number of pages9
JournalJournal of Clinical Periodontology
Volume31
Issue number9
DOIs
StatePublished - Sep 1 2004

Fingerprint

Dogs
Osteogenesis
Inlays
Biocompatible Materials
Bone and Bones
calcium phosphate
recombinant human bone morphogenetic protein-2
Ceredex
Root Resorption
Technology
Newfoundland and Labrador
Dental Cementum
Ankylosis
Periodontal Ligament
Orthopedics
Wounds and Injuries

Keywords

  • Bone induction
  • Calcium phosphate
  • Periodontal regeneration
  • Tissue engineering

ASJC Scopus subject areas

  • Periodontics

Cite this

Periodontal repair in dogs : Evaluation of a bioresorbable calcium phosphate cement (Ceredex™) as a carrier for rhBMP-2. / Sorensen, Rachel G.; Wikesjö, Ulf M E; Kinoshita, Atsuhiro; Wozney, John M.

In: Journal of Clinical Periodontology, Vol. 31, No. 9, 01.09.2004, p. 796-804.

Research output: Contribution to journalArticle

Sorensen, Rachel G. ; Wikesjö, Ulf M E ; Kinoshita, Atsuhiro ; Wozney, John M. / Periodontal repair in dogs : Evaluation of a bioresorbable calcium phosphate cement (Ceredex™) as a carrier for rhBMP-2. In: Journal of Clinical Periodontology. 2004 ; Vol. 31, No. 9. pp. 796-804.
@article{ec9d2ec24e574c4098b86aa71993692d,
title = "Periodontal repair in dogs: Evaluation of a bioresorbable calcium phosphate cement (Ceredex™) as a carrier for rhBMP-2",
abstract = "Background: Recombinant human bone morphogenetic protein-2 (rhBMP-2) has been shown to induce clinically relevant bone formation for orthopedic, craniofacial, and oral indications. It appears critical, in particular for onlay indications, that the associated carrier technology exhibits structural integrity to offset compressive forces in support of rhBMP-2-induced bone formation. The objective of this study was to evaluate a calcium phosphate (CP) cement, Ceredex™, as a candidate carrier for rhBMP-2 in a defect model with limited osteogenic potential. Materials: Bilateral, critical size, 6-mm, supra-alveolar, periodontal defects were created in six, adult, male, Hound Labrador mongrels. Three animals received rhBMP-2/Ceredex™ (rhBMP-2 at 0.20 and 0.40 mg/ml) in contralateral defect sites (implant volume/defect ∼ 1 ml). One defect site in each of the three remaining animals received Ceredex™ without rhBMP-2 (control). The animals were euthanized at 1.2 weeks postsurgery for histologic and histometric analysis. Results: Mean induced bone height exceeded 80{\%} of the defect height for supra-alveolar periodontal defects receiving rhBMP-2/Ceredex™ without major differences between rhBMP-2 concentrations compared with approximately 40{\%} for the control. The newly formed bone, a mixture of lamellar and woven bone in fibrovascular tissue, circumscribed relatively large portions of the residual Ceredex™ biomaterial. Inflammatory lesions were associated with limited bone formation in some sites. From a periodontal perspective, sites receiving rhBMP-2/Ceredex™ exhibited increased cementum formation compared with control, but without a functionally oriented periodontal ligament, and increased ankylosis and root resorption. Control sites exhibited early wound failure and exposure, loss of the Ceredex™ biomaterial, and limited bone formation. Conclusions: The Ceredex™ CP cement appears a potentially promising carrier technology for rhBMP-2 onlay indications. However, a slow resorption rate may prevent its wider use. This study does not support use of the rhBMP-2/Ceredex™ combination for periodontal indications.",
keywords = "Bone induction, Calcium phosphate, Periodontal regeneration, Tissue engineering",
author = "Sorensen, {Rachel G.} and Wikesj{\"o}, {Ulf M E} and Atsuhiro Kinoshita and Wozney, {John M.}",
year = "2004",
month = "9",
day = "1",
doi = "10.1111/j.1600-051X.2004.00544.x",
language = "English (US)",
volume = "31",
pages = "796--804",
journal = "Journal of Clinical Periodontology",
issn = "0303-6979",
publisher = "Blackwell Munksgaard",
number = "9",

}

TY - JOUR

T1 - Periodontal repair in dogs

T2 - Evaluation of a bioresorbable calcium phosphate cement (Ceredex™) as a carrier for rhBMP-2

AU - Sorensen, Rachel G.

AU - Wikesjö, Ulf M E

AU - Kinoshita, Atsuhiro

AU - Wozney, John M.

PY - 2004/9/1

Y1 - 2004/9/1

N2 - Background: Recombinant human bone morphogenetic protein-2 (rhBMP-2) has been shown to induce clinically relevant bone formation for orthopedic, craniofacial, and oral indications. It appears critical, in particular for onlay indications, that the associated carrier technology exhibits structural integrity to offset compressive forces in support of rhBMP-2-induced bone formation. The objective of this study was to evaluate a calcium phosphate (CP) cement, Ceredex™, as a candidate carrier for rhBMP-2 in a defect model with limited osteogenic potential. Materials: Bilateral, critical size, 6-mm, supra-alveolar, periodontal defects were created in six, adult, male, Hound Labrador mongrels. Three animals received rhBMP-2/Ceredex™ (rhBMP-2 at 0.20 and 0.40 mg/ml) in contralateral defect sites (implant volume/defect ∼ 1 ml). One defect site in each of the three remaining animals received Ceredex™ without rhBMP-2 (control). The animals were euthanized at 1.2 weeks postsurgery for histologic and histometric analysis. Results: Mean induced bone height exceeded 80% of the defect height for supra-alveolar periodontal defects receiving rhBMP-2/Ceredex™ without major differences between rhBMP-2 concentrations compared with approximately 40% for the control. The newly formed bone, a mixture of lamellar and woven bone in fibrovascular tissue, circumscribed relatively large portions of the residual Ceredex™ biomaterial. Inflammatory lesions were associated with limited bone formation in some sites. From a periodontal perspective, sites receiving rhBMP-2/Ceredex™ exhibited increased cementum formation compared with control, but without a functionally oriented periodontal ligament, and increased ankylosis and root resorption. Control sites exhibited early wound failure and exposure, loss of the Ceredex™ biomaterial, and limited bone formation. Conclusions: The Ceredex™ CP cement appears a potentially promising carrier technology for rhBMP-2 onlay indications. However, a slow resorption rate may prevent its wider use. This study does not support use of the rhBMP-2/Ceredex™ combination for periodontal indications.

AB - Background: Recombinant human bone morphogenetic protein-2 (rhBMP-2) has been shown to induce clinically relevant bone formation for orthopedic, craniofacial, and oral indications. It appears critical, in particular for onlay indications, that the associated carrier technology exhibits structural integrity to offset compressive forces in support of rhBMP-2-induced bone formation. The objective of this study was to evaluate a calcium phosphate (CP) cement, Ceredex™, as a candidate carrier for rhBMP-2 in a defect model with limited osteogenic potential. Materials: Bilateral, critical size, 6-mm, supra-alveolar, periodontal defects were created in six, adult, male, Hound Labrador mongrels. Three animals received rhBMP-2/Ceredex™ (rhBMP-2 at 0.20 and 0.40 mg/ml) in contralateral defect sites (implant volume/defect ∼ 1 ml). One defect site in each of the three remaining animals received Ceredex™ without rhBMP-2 (control). The animals were euthanized at 1.2 weeks postsurgery for histologic and histometric analysis. Results: Mean induced bone height exceeded 80% of the defect height for supra-alveolar periodontal defects receiving rhBMP-2/Ceredex™ without major differences between rhBMP-2 concentrations compared with approximately 40% for the control. The newly formed bone, a mixture of lamellar and woven bone in fibrovascular tissue, circumscribed relatively large portions of the residual Ceredex™ biomaterial. Inflammatory lesions were associated with limited bone formation in some sites. From a periodontal perspective, sites receiving rhBMP-2/Ceredex™ exhibited increased cementum formation compared with control, but without a functionally oriented periodontal ligament, and increased ankylosis and root resorption. Control sites exhibited early wound failure and exposure, loss of the Ceredex™ biomaterial, and limited bone formation. Conclusions: The Ceredex™ CP cement appears a potentially promising carrier technology for rhBMP-2 onlay indications. However, a slow resorption rate may prevent its wider use. This study does not support use of the rhBMP-2/Ceredex™ combination for periodontal indications.

KW - Bone induction

KW - Calcium phosphate

KW - Periodontal regeneration

KW - Tissue engineering

UR - http://www.scopus.com/inward/record.url?scp=4444275586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444275586&partnerID=8YFLogxK

U2 - 10.1111/j.1600-051X.2004.00544.x

DO - 10.1111/j.1600-051X.2004.00544.x

M3 - Article

VL - 31

SP - 796

EP - 804

JO - Journal of Clinical Periodontology

JF - Journal of Clinical Periodontology

SN - 0303-6979

IS - 9

ER -